Insider · CIK 0001835208
Annie Yoshiyama
Files at ALLO (Allogene Therapeutics, Inc.). First filing Apr 23, 2025, latest Apr 23, 2026.
In brief
Annie Yoshiyama files SEC Form 4 as officer at ALLO (Allogene Therapeutics, Inc.). Since Apr 23, 2025, Annie Yoshiyama has reported 0 open-market buys worth $0 and 3 open-market sells worth $43k, the latest filed on Apr 23, 2026.
A track record needs three past buys with six months of prices behind them; Annie Yoshiyama has 0, so none is measured yet.
The newest scored trade: sold $22k of ALLO on Apr 21, 2026, filed Apr 23, 2026, scored 15 (weak). In the last 12 months: 0 buys worth $0 and 2 sells worth $29k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ALLO: Allogene Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | ALLOsell Allogene Therapeutics, Inc. | $22k 9,586 shares | -7% | +144% from low-24% from high | |
| 30Weak | Allogene Therapeutics, Inc. | $7,167 4,167 shares | -3% | +97% from low-34% from high | |
| 15Weak | ALLOsell Allogene Therapeutics, Inc. | $14k 9,601 shares | -7% | +4% from low-56% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Apr 21, 2026 | ALLO Allogene Therapeutics, Inc. | 9,586 0.00% of outstanding | $22k | Apr 21, 2026 | none |
| Feb 2, 2026 | ALLO ALLOGENE THERAPEUTICS, INC. | 4,167 0.00% of outstanding | $7,178 | Feb 2, 2026 | none |
| Apr 21, 2025 | ALLO Allogene Therapeutics, Inc. | 9,601 0.00% of outstanding | $14k | Apr 21, 2025 | none |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 21, 2026 | ALLO Allogene Therapeutics, Inc. | SOpen-market sale Common Stock | -9,586 | $2.31 | $22k | 124,517 | Apr 23, 2026 |
| Feb 2, 2026 | ALLO Allogene Therapeutics, Inc. | SOpen-market sale Common Stock | -4,167 | $1.72 | $7,167 | 130,322 | Feb 4, 2026 |
| Feb 2, 2026 | ALLO Allogene Therapeutics, Inc. | AGrant or award Stock Option (Right to buy)derivative | +179,691 | $0.00 | $0 | 179,691 | Feb 4, 2026 |
| Feb 2, 2026 | ALLO Allogene Therapeutics, Inc. | AGrant or award Restricted Stock Unitderivative | +50,827 | $0.00 | $0 | 50,827 | Feb 4, 2026 |
| Apr 21, 2025 | ALLO Allogene Therapeutics, Inc. | SOpen-market sale Common Stock | -9,601 | $1.41 | $14k | 130,663 | Apr 23, 2025 |
| Jan 24, 2025 | ALLO Allogene Therapeutics, Inc. | AGrant or award Common Stock | +36,232 | $0.00 | $0 | 137,990 | Jan 28, 2025 |
| Jan 24, 2025 | ALLO Allogene Therapeutics, Inc. | AGrant or award Stock Option (Right to buy)derivative | +128,093 | $0.00 | $0 | 128,093 | Jan 28, 2025 |
Questions about Annie Yoshiyama
Answered from the filings on this page, as of the latest one.
Is Annie Yoshiyama buying or selling?
In the last 12 months Annie Yoshiyama reported 0 open-market buys worth $0 and 2 open-market sells worth $29k on SEC Form 4; the latest was sold $22k of ALLO on Apr 21, 2026. Grants, option exercises and tax withholding are not counted.
How did Annie Yoshiyama's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Annie Yoshiyama has 0.
Where does Annie Yoshiyama file Form 4?
Annie Yoshiyama has filed Form 4 at ALLO (Allogene Therapeutics, Inc.) as SVP, Finance. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.